Condition
Adverse Effect of Other Antipsychotics and Neuroleptics
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Early P 1 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02708394Early Phase 1CompletedPrimary
Molecular Mechanisms of Antipsychotic-induced Insulin Resistance
NCT02604056Not ApplicableCompletedPrimary
Pragmatic Cluster Trial for Nursing Home Antipsychotic Prescribing
NCT01966588UnknownPrimary
Adverse Events and Genomics in Schizophrenia
Showing all 3 trials